{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "573d53a3",
   "metadata": {},
   "source": [
    "# 1. Clinical Trial Dataset ‚Äì Cleaning & Initial Exploration\n",
    "\n",
    "### üî∑ Goal of This Notebook:\n",
    "\n",
    "#### Load raw dataset\n",
    "#### Inspect structure, missing values, and data types\n",
    "#### Clean and preprocess data for modeling\n",
    "#### Save a cleaned version of the dataset"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "bb7fa2ed",
   "metadata": {},
   "source": [
    "### Import Required Libraries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "5b4e48ee",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Data handling\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "\n",
    "# Visualization\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "\n",
    "# System & warnings\n",
    "import warnings\n",
    "warnings.filterwarnings('ignore')\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "4e9673f8",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load the dataset and make Copy \n",
    "df_raw = pd.read_csv('../data/processed/merged_trials.csv')\n",
    "\n",
    "# Making copy\n",
    "df = pd.DataFrame(df_raw.copy())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "a9e310c9",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Shape: (6676, 30)\n"
     ]
    }
   ],
   "source": [
    "# Shape of dataset\n",
    "print(\"Shape:\", df_raw.shape)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "863c56d9",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "RangeIndex: 6676 entries, 0 to 6675\n",
      "Data columns (total 30 columns):\n",
      " #   Column                      Non-Null Count  Dtype  \n",
      "---  ------                      --------------  -----  \n",
      " 0   NCT Number                  6676 non-null   object \n",
      " 1   Study Title                 6676 non-null   object \n",
      " 2   Study URL                   6676 non-null   object \n",
      " 3   Acronym                     2339 non-null   object \n",
      " 4   Study Status                6676 non-null   object \n",
      " 5   Brief Summary               6676 non-null   object \n",
      " 6   Study Results               6676 non-null   object \n",
      " 7   Conditions                  6676 non-null   object \n",
      " 8   Interventions               6676 non-null   object \n",
      " 9   Primary Outcome Measures    6676 non-null   object \n",
      " 10  Secondary Outcome Measures  5965 non-null   object \n",
      " 11  Other Outcome Measures      855 non-null    object \n",
      " 12  Sponsor                     6676 non-null   object \n",
      " 13  Collaborators               2241 non-null   object \n",
      " 14  Sex                         6676 non-null   object \n",
      " 15  Age                         6676 non-null   object \n",
      " 16  Phases                      6676 non-null   object \n",
      " 17  Enrollment                  6676 non-null   int64  \n",
      " 18  Funder Type                 6676 non-null   object \n",
      " 19  Study Type                  6676 non-null   object \n",
      " 20  Study Design                6676 non-null   object \n",
      " 21  Other IDs                   6676 non-null   object \n",
      " 22  Start Date                  6676 non-null   object \n",
      " 23  Primary Completion Date     6676 non-null   object \n",
      " 24  Completion Date             6675 non-null   object \n",
      " 25  First Posted                6676 non-null   object \n",
      " 26  Results First Posted        0 non-null      float64\n",
      " 27  Last Update Posted          6676 non-null   object \n",
      " 28  Locations                   5972 non-null   object \n",
      " 29  Study Documents             96 non-null     object \n",
      "dtypes: float64(1), int64(1), object(28)\n",
      "memory usage: 1.5+ MB\n"
     ]
    }
   ],
   "source": [
    "# Info of dataset\n",
    "df_raw.info()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "02280039",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Enrollment</th>\n",
       "      <th>Results First Posted</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>count</th>\n",
       "      <td>6676.000000</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>mean</th>\n",
       "      <td>272.326992</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>std</th>\n",
       "      <td>1209.673709</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>min</th>\n",
       "      <td>1.000000</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25%</th>\n",
       "      <td>41.000000</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50%</th>\n",
       "      <td>90.000000</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75%</th>\n",
       "      <td>220.000000</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>max</th>\n",
       "      <td>70000.000000</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         Enrollment  Results First Posted\n",
       "count   6676.000000                   0.0\n",
       "mean     272.326992                   NaN\n",
       "std     1209.673709                   NaN\n",
       "min        1.000000                   NaN\n",
       "25%       41.000000                   NaN\n",
       "50%       90.000000                   NaN\n",
       "75%      220.000000                   NaN\n",
       "max    70000.000000                   NaN"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Statistical summary\n",
    "df_raw.describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "4dfb33bf",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Columns:\n",
      " ['NCT Number', 'Study Title', 'Study URL', 'Acronym', 'Study Status', 'Brief Summary', 'Study Results', 'Conditions', 'Interventions', 'Primary Outcome Measures', 'Secondary Outcome Measures', 'Other Outcome Measures', 'Sponsor', 'Collaborators', 'Sex', 'Age', 'Phases', 'Enrollment', 'Funder Type', 'Study Type', 'Study Design', 'Other IDs', 'Start Date', 'Primary Completion Date', 'Completion Date', 'First Posted', 'Results First Posted', 'Last Update Posted', 'Locations', 'Study Documents']\n"
     ]
    }
   ],
   "source": [
    "# Column names\n",
    "print(\"Columns:\\n\", df_raw.columns.tolist())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "7e772049",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Head:\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>NCT Number</th>\n",
       "      <th>Study Title</th>\n",
       "      <th>Study URL</th>\n",
       "      <th>Acronym</th>\n",
       "      <th>Study Status</th>\n",
       "      <th>Brief Summary</th>\n",
       "      <th>Study Results</th>\n",
       "      <th>Conditions</th>\n",
       "      <th>Interventions</th>\n",
       "      <th>Primary Outcome Measures</th>\n",
       "      <th>...</th>\n",
       "      <th>Study Design</th>\n",
       "      <th>Other IDs</th>\n",
       "      <th>Start Date</th>\n",
       "      <th>Primary Completion Date</th>\n",
       "      <th>Completion Date</th>\n",
       "      <th>First Posted</th>\n",
       "      <th>Results First Posted</th>\n",
       "      <th>Last Update Posted</th>\n",
       "      <th>Locations</th>\n",
       "      <th>Study Documents</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT06767735</td>\n",
       "      <td>A Phase III Clinical Study to Assess the Effic...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT06767735</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NOT_YET_RECRUITING</td>\n",
       "      <td>This study will be conducted to compare the ef...</td>\n",
       "      <td>NO</td>\n",
       "      <td>Diabetes</td>\n",
       "      <td>DRUG: GZR4|DRUG: Insulin Glargine U100</td>\n",
       "      <td>Change in HbA1c, From baseline (week 0) to wee...</td>\n",
       "      <td>...</td>\n",
       "      <td>Allocation: RANDOMIZED|Intervention Model: PAR...</td>\n",
       "      <td>GZR4-T2D-301</td>\n",
       "      <td>2025-02-14</td>\n",
       "      <td>2026-02-02</td>\n",
       "      <td>2026-08-17</td>\n",
       "      <td>2025-01-10</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2025-01-10</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT06767748</td>\n",
       "      <td>A Phase III Clinical Study to Assess the Effic...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT06767748</td>\n",
       "      <td>NaN</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>This study will be conducted to compare the ef...</td>\n",
       "      <td>NO</td>\n",
       "      <td>Diabetes</td>\n",
       "      <td>DRUG: GZR4|DRUG: insulin degludec</td>\n",
       "      <td>Change in HbA1c, From baseline (week 0) to wee...</td>\n",
       "      <td>...</td>\n",
       "      <td>Allocation: RANDOMIZED|Intervention Model: PAR...</td>\n",
       "      <td>GZR4-T2D-302</td>\n",
       "      <td>2025-02-17</td>\n",
       "      <td>2026-02-07</td>\n",
       "      <td>2026-02-28</td>\n",
       "      <td>2025-01-10</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2025-04-04</td>\n",
       "      <td>Gan &amp; Lee Pharmaceuticals Shandong Co., Ltd., ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT06767761</td>\n",
       "      <td>A Phase III Clinical Study to Assess the Effic...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT06767761</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NOT_YET_RECRUITING</td>\n",
       "      <td>This study will be conducted to compare the ef...</td>\n",
       "      <td>NO</td>\n",
       "      <td>Diabetes</td>\n",
       "      <td>DRUG: GZR4|DRUG: Insulin Glargine U100 group</td>\n",
       "      <td>Change in HbA1c, From baseline (week 0) to wee...</td>\n",
       "      <td>...</td>\n",
       "      <td>Allocation: RANDOMIZED|Intervention Model: PAR...</td>\n",
       "      <td>GZR4-T2D-303</td>\n",
       "      <td>2025-02-14</td>\n",
       "      <td>2026-03-19</td>\n",
       "      <td>2026-04-09</td>\n",
       "      <td>2025-01-10</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2025-01-10</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT06305286</td>\n",
       "      <td>Safety, Tolerability, and Efficacy of Immunomo...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT06305286</td>\n",
       "      <td>NaN</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>AT-1501 is a monoclonal antibody. Antibodies a...</td>\n",
       "      <td>NO</td>\n",
       "      <td>Diabetes Mellitus</td>\n",
       "      <td>DRUG: AT-1501</td>\n",
       "      <td>Number of Participants who are insulin-indepen...</td>\n",
       "      <td>...</td>\n",
       "      <td>Allocation: NON_RANDOMIZED|Intervention Model:...</td>\n",
       "      <td>IRB23-1367</td>\n",
       "      <td>2024-03-04</td>\n",
       "      <td>2029-03</td>\n",
       "      <td>2029-03</td>\n",
       "      <td>2024-03-12</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2024-09-19</td>\n",
       "      <td>University of Chicago, Chicago, Illinois, 6063...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT06727721</td>\n",
       "      <td>Safety and Efficacy of OCN19-overexpressed Hum...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT06727721</td>\n",
       "      <td>NaN</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>Umbilical cord mesenchymal stem cell injection...</td>\n",
       "      <td>NO</td>\n",
       "      <td>Diabetes|Type 2 Diabetes</td>\n",
       "      <td>BIOLOGICAL: mesenchymal stem cells with OCN-19...</td>\n",
       "      <td>Daily insulin dose is used, From enrollment to...</td>\n",
       "      <td>...</td>\n",
       "      <td>Allocation: RANDOMIZED|Intervention Model: PAR...</td>\n",
       "      <td>CHEC2023-226</td>\n",
       "      <td>2023-11-06</td>\n",
       "      <td>2028-12-12</td>\n",
       "      <td>2029-12-12</td>\n",
       "      <td>2024-12-11</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2024-12-17</td>\n",
       "      <td>Changhai Hospital, Shanghai, China</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows √ó 30 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    NCT Number                                        Study Title  \\\n",
       "0  NCT06767735  A Phase III Clinical Study to Assess the Effic...   \n",
       "1  NCT06767748  A Phase III Clinical Study to Assess the Effic...   \n",
       "2  NCT06767761  A Phase III Clinical Study to Assess the Effic...   \n",
       "3  NCT06305286  Safety, Tolerability, and Efficacy of Immunomo...   \n",
       "4  NCT06727721  Safety and Efficacy of OCN19-overexpressed Hum...   \n",
       "\n",
       "                                      Study URL Acronym        Study Status  \\\n",
       "0  https://clinicaltrials.gov/study/NCT06767735     NaN  NOT_YET_RECRUITING   \n",
       "1  https://clinicaltrials.gov/study/NCT06767748     NaN          RECRUITING   \n",
       "2  https://clinicaltrials.gov/study/NCT06767761     NaN  NOT_YET_RECRUITING   \n",
       "3  https://clinicaltrials.gov/study/NCT06305286     NaN          RECRUITING   \n",
       "4  https://clinicaltrials.gov/study/NCT06727721     NaN          RECRUITING   \n",
       "\n",
       "                                       Brief Summary Study Results  \\\n",
       "0  This study will be conducted to compare the ef...            NO   \n",
       "1  This study will be conducted to compare the ef...            NO   \n",
       "2  This study will be conducted to compare the ef...            NO   \n",
       "3  AT-1501 is a monoclonal antibody. Antibodies a...            NO   \n",
       "4  Umbilical cord mesenchymal stem cell injection...            NO   \n",
       "\n",
       "                 Conditions  \\\n",
       "0                  Diabetes   \n",
       "1                  Diabetes   \n",
       "2                  Diabetes   \n",
       "3         Diabetes Mellitus   \n",
       "4  Diabetes|Type 2 Diabetes   \n",
       "\n",
       "                                       Interventions  \\\n",
       "0             DRUG: GZR4|DRUG: Insulin Glargine U100   \n",
       "1                  DRUG: GZR4|DRUG: insulin degludec   \n",
       "2       DRUG: GZR4|DRUG: Insulin Glargine U100 group   \n",
       "3                                      DRUG: AT-1501   \n",
       "4  BIOLOGICAL: mesenchymal stem cells with OCN-19...   \n",
       "\n",
       "                            Primary Outcome Measures  ...  \\\n",
       "0  Change in HbA1c, From baseline (week 0) to wee...  ...   \n",
       "1  Change in HbA1c, From baseline (week 0) to wee...  ...   \n",
       "2  Change in HbA1c, From baseline (week 0) to wee...  ...   \n",
       "3  Number of Participants who are insulin-indepen...  ...   \n",
       "4  Daily insulin dose is used, From enrollment to...  ...   \n",
       "\n",
       "                                        Study Design     Other IDs  \\\n",
       "0  Allocation: RANDOMIZED|Intervention Model: PAR...  GZR4-T2D-301   \n",
       "1  Allocation: RANDOMIZED|Intervention Model: PAR...  GZR4-T2D-302   \n",
       "2  Allocation: RANDOMIZED|Intervention Model: PAR...  GZR4-T2D-303   \n",
       "3  Allocation: NON_RANDOMIZED|Intervention Model:...    IRB23-1367   \n",
       "4  Allocation: RANDOMIZED|Intervention Model: PAR...  CHEC2023-226   \n",
       "\n",
       "   Start Date Primary Completion Date Completion Date First Posted  \\\n",
       "0  2025-02-14              2026-02-02      2026-08-17   2025-01-10   \n",
       "1  2025-02-17              2026-02-07      2026-02-28   2025-01-10   \n",
       "2  2025-02-14              2026-03-19      2026-04-09   2025-01-10   \n",
       "3  2024-03-04                 2029-03         2029-03   2024-03-12   \n",
       "4  2023-11-06              2028-12-12      2029-12-12   2024-12-11   \n",
       "\n",
       "  Results First Posted  Last Update Posted  \\\n",
       "0                  NaN          2025-01-10   \n",
       "1                  NaN          2025-04-04   \n",
       "2                  NaN          2025-01-10   \n",
       "3                  NaN          2024-09-19   \n",
       "4                  NaN          2024-12-17   \n",
       "\n",
       "                                           Locations Study Documents  \n",
       "0                                                NaN             NaN  \n",
       "1  Gan & Lee Pharmaceuticals Shandong Co., Ltd., ...             NaN  \n",
       "2                                                NaN             NaN  \n",
       "3  University of Chicago, Chicago, Illinois, 6063...             NaN  \n",
       "4                 Changhai Hospital, Shanghai, China             NaN  \n",
       "\n",
       "[5 rows x 30 columns]"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Preview of data\n",
    "print(\"Head:\") \n",
    "df_raw.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "06582fae",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Tail:\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>NCT Number</th>\n",
       "      <th>Study Title</th>\n",
       "      <th>Study URL</th>\n",
       "      <th>Acronym</th>\n",
       "      <th>Study Status</th>\n",
       "      <th>Brief Summary</th>\n",
       "      <th>Study Results</th>\n",
       "      <th>Conditions</th>\n",
       "      <th>Interventions</th>\n",
       "      <th>Primary Outcome Measures</th>\n",
       "      <th>...</th>\n",
       "      <th>Study Design</th>\n",
       "      <th>Other IDs</th>\n",
       "      <th>Start Date</th>\n",
       "      <th>Primary Completion Date</th>\n",
       "      <th>Completion Date</th>\n",
       "      <th>First Posted</th>\n",
       "      <th>Results First Posted</th>\n",
       "      <th>Last Update Posted</th>\n",
       "      <th>Locations</th>\n",
       "      <th>Study Documents</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>6671</th>\n",
       "      <td>NCT05946564</td>\n",
       "      <td>A Trial to Evaluate the Efficacy of Pioglitazo...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT05946564</td>\n",
       "      <td>RENATO</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>The RENATO trial is a multicenter randomized c...</td>\n",
       "      <td>NO</td>\n",
       "      <td>ANCA Associated Vasculitis|Rapidly Progressive...</td>\n",
       "      <td>DRUG: Pioglitazone (ACTOS¬Æ)|DRUG: Placebo of P...</td>\n",
       "      <td>Appearance of a success defined as (1) Delta s...</td>\n",
       "      <td>...</td>\n",
       "      <td>Allocation: RANDOMIZED|Intervention Model: PAR...</td>\n",
       "      <td>APHP211045|2022-501057-36-00|PHRC-20-0707</td>\n",
       "      <td>2023-10-24</td>\n",
       "      <td>2027-04-24</td>\n",
       "      <td>2027-10-24</td>\n",
       "      <td>2023-07-14</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2024-07-11</td>\n",
       "      <td>CHU Amiens, Amiens, 80000, France|CH de Boulog...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6672</th>\n",
       "      <td>NCT03482479</td>\n",
       "      <td>Low Dose Naltrexone to Improve Physical Health...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT03482479</td>\n",
       "      <td>LoDoNaVasc</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>Naltrexone is an FDA approved drug (for alcoho...</td>\n",
       "      <td>NO</td>\n",
       "      <td>Eosinophilic Granulomatosis With Polyangiitis ...</td>\n",
       "      <td>DRUG: Naltrexone Hydrochloride|OTHER: Placebo ...</td>\n",
       "      <td>PROMIS Global Physical Health, Questionnaire a...</td>\n",
       "      <td>...</td>\n",
       "      <td>Allocation: RANDOMIZED|Intervention Model: CRO...</td>\n",
       "      <td>VCRC5564</td>\n",
       "      <td>2019-02-04</td>\n",
       "      <td>2025-12-31</td>\n",
       "      <td>2025-12-31</td>\n",
       "      <td>2018-03-29</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2025-04-11</td>\n",
       "      <td>Brigham and Women's Hospital, Boston, Massachu...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6673</th>\n",
       "      <td>NCT06220123</td>\n",
       "      <td>A Study to Evaluate the Efficacy and Safety of...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT06220123</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NOT_YET_RECRUITING</td>\n",
       "      <td>This study is designed to evaluate the efficac...</td>\n",
       "      <td>NO</td>\n",
       "      <td>Preventing Postoperative Venous Thromboembolis...</td>\n",
       "      <td>DRUG: SHR-2004|DRUG: Enoxaparin Sodium Injecti...</td>\n",
       "      <td>Primary efficacy endpoint: The incidence rate ...</td>\n",
       "      <td>...</td>\n",
       "      <td>Allocation: RANDOMIZED|Intervention Model: PAR...</td>\n",
       "      <td>SHR-2004-202</td>\n",
       "      <td>2024-01-31</td>\n",
       "      <td>2025-06-04</td>\n",
       "      <td>2025-07-31</td>\n",
       "      <td>2024-01-23</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2024-01-23</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6674</th>\n",
       "      <td>NCT06947473</td>\n",
       "      <td>Umbilical Cord Blood CD19-BCMA CART Cell Thera...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT06947473</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NOT_YET_RECRUITING</td>\n",
       "      <td>This is a single-center, open-label, non-rando...</td>\n",
       "      <td>NO</td>\n",
       "      <td>Refractory Lupus Nephritis|Systemic Sclerosis|...</td>\n",
       "      <td>DRUG: umbilical cord blood CD19-BCMA CAR-T cel...</td>\n",
       "      <td>Dose-limiting toxicity (DLT), Incidence and ty...</td>\n",
       "      <td>...</td>\n",
       "      <td>Allocation: NA|Intervention Model: SINGLE_GROU...</td>\n",
       "      <td>BJGBYY-IIT-LCYJ-2025-025</td>\n",
       "      <td>2025-04-18</td>\n",
       "      <td>2026-07-01</td>\n",
       "      <td>2026-07-31</td>\n",
       "      <td>2025-04-27</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2025-04-30</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6675</th>\n",
       "      <td>NCT06947460</td>\n",
       "      <td>CD19-BCMA CART Cell Therapy for Refractory SLE...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT06947460</td>\n",
       "      <td>NaN</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>This is a single-center, open-label, non-rando...</td>\n",
       "      <td>NO</td>\n",
       "      <td>Refractory Lupus Nephritis|Systemic Sclerosis|...</td>\n",
       "      <td>DRUG: CD19-BCMA CAR-T cells infusion</td>\n",
       "      <td>Dose-limiting toxicity (DLT), Incidence and ty...</td>\n",
       "      <td>...</td>\n",
       "      <td>Allocation: NA|Intervention Model: SINGLE_GROU...</td>\n",
       "      <td>BJGBYY-IIT-LCYJ-2025-024</td>\n",
       "      <td>2025-04-18</td>\n",
       "      <td>2026-07-01</td>\n",
       "      <td>2026-07-31</td>\n",
       "      <td>2025-04-27</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2025-05-13</td>\n",
       "      <td>Âåó‰∫¨È´òÂçöÂåªÈô¢, Âåó‰∫¨, Âåó‰∫¨Â∏ÇÊòåÂπ≥Âå∫, 102200, China</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows √ó 30 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "       NCT Number                                        Study Title  \\\n",
       "6671  NCT05946564  A Trial to Evaluate the Efficacy of Pioglitazo...   \n",
       "6672  NCT03482479  Low Dose Naltrexone to Improve Physical Health...   \n",
       "6673  NCT06220123  A Study to Evaluate the Efficacy and Safety of...   \n",
       "6674  NCT06947473  Umbilical Cord Blood CD19-BCMA CART Cell Thera...   \n",
       "6675  NCT06947460  CD19-BCMA CART Cell Therapy for Refractory SLE...   \n",
       "\n",
       "                                         Study URL     Acronym  \\\n",
       "6671  https://clinicaltrials.gov/study/NCT05946564      RENATO   \n",
       "6672  https://clinicaltrials.gov/study/NCT03482479  LoDoNaVasc   \n",
       "6673  https://clinicaltrials.gov/study/NCT06220123         NaN   \n",
       "6674  https://clinicaltrials.gov/study/NCT06947473         NaN   \n",
       "6675  https://clinicaltrials.gov/study/NCT06947460         NaN   \n",
       "\n",
       "            Study Status                                      Brief Summary  \\\n",
       "6671          RECRUITING  The RENATO trial is a multicenter randomized c...   \n",
       "6672          RECRUITING  Naltrexone is an FDA approved drug (for alcoho...   \n",
       "6673  NOT_YET_RECRUITING  This study is designed to evaluate the efficac...   \n",
       "6674  NOT_YET_RECRUITING  This is a single-center, open-label, non-rando...   \n",
       "6675          RECRUITING  This is a single-center, open-label, non-rando...   \n",
       "\n",
       "     Study Results                                         Conditions  \\\n",
       "6671            NO  ANCA Associated Vasculitis|Rapidly Progressive...   \n",
       "6672            NO  Eosinophilic Granulomatosis With Polyangiitis ...   \n",
       "6673            NO  Preventing Postoperative Venous Thromboembolis...   \n",
       "6674            NO  Refractory Lupus Nephritis|Systemic Sclerosis|...   \n",
       "6675            NO  Refractory Lupus Nephritis|Systemic Sclerosis|...   \n",
       "\n",
       "                                          Interventions  \\\n",
       "6671  DRUG: Pioglitazone (ACTOS¬Æ)|DRUG: Placebo of P...   \n",
       "6672  DRUG: Naltrexone Hydrochloride|OTHER: Placebo ...   \n",
       "6673  DRUG: SHR-2004|DRUG: Enoxaparin Sodium Injecti...   \n",
       "6674  DRUG: umbilical cord blood CD19-BCMA CAR-T cel...   \n",
       "6675               DRUG: CD19-BCMA CAR-T cells infusion   \n",
       "\n",
       "                               Primary Outcome Measures  ...  \\\n",
       "6671  Appearance of a success defined as (1) Delta s...  ...   \n",
       "6672  PROMIS Global Physical Health, Questionnaire a...  ...   \n",
       "6673  Primary efficacy endpoint: The incidence rate ...  ...   \n",
       "6674  Dose-limiting toxicity (DLT), Incidence and ty...  ...   \n",
       "6675  Dose-limiting toxicity (DLT), Incidence and ty...  ...   \n",
       "\n",
       "                                           Study Design  \\\n",
       "6671  Allocation: RANDOMIZED|Intervention Model: PAR...   \n",
       "6672  Allocation: RANDOMIZED|Intervention Model: CRO...   \n",
       "6673  Allocation: RANDOMIZED|Intervention Model: PAR...   \n",
       "6674  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
       "6675  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
       "\n",
       "                                      Other IDs  Start Date  \\\n",
       "6671  APHP211045|2022-501057-36-00|PHRC-20-0707  2023-10-24   \n",
       "6672                                   VCRC5564  2019-02-04   \n",
       "6673                               SHR-2004-202  2024-01-31   \n",
       "6674                   BJGBYY-IIT-LCYJ-2025-025  2025-04-18   \n",
       "6675                   BJGBYY-IIT-LCYJ-2025-024  2025-04-18   \n",
       "\n",
       "     Primary Completion Date Completion Date First Posted  \\\n",
       "6671              2027-04-24      2027-10-24   2023-07-14   \n",
       "6672              2025-12-31      2025-12-31   2018-03-29   \n",
       "6673              2025-06-04      2025-07-31   2024-01-23   \n",
       "6674              2026-07-01      2026-07-31   2025-04-27   \n",
       "6675              2026-07-01      2026-07-31   2025-04-27   \n",
       "\n",
       "     Results First Posted  Last Update Posted  \\\n",
       "6671                  NaN          2024-07-11   \n",
       "6672                  NaN          2025-04-11   \n",
       "6673                  NaN          2024-01-23   \n",
       "6674                  NaN          2025-04-30   \n",
       "6675                  NaN          2025-05-13   \n",
       "\n",
       "                                              Locations Study Documents  \n",
       "6671  CHU Amiens, Amiens, 80000, France|CH de Boulog...             NaN  \n",
       "6672  Brigham and Women's Hospital, Boston, Massachu...             NaN  \n",
       "6673                                                NaN             NaN  \n",
       "6674                                                NaN             NaN  \n",
       "6675                  Âåó‰∫¨È´òÂçöÂåªÈô¢, Âåó‰∫¨, Âåó‰∫¨Â∏ÇÊòåÂπ≥Âå∫, 102200, China             NaN  \n",
       "\n",
       "[5 rows x 30 columns]"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "print(\"Tail:\")\n",
    "df_raw.tail()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "01f4bf16",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Data Types:\n",
      " NCT Number                     object\n",
      "Study Title                    object\n",
      "Study URL                      object\n",
      "Acronym                        object\n",
      "Study Status                   object\n",
      "Brief Summary                  object\n",
      "Study Results                  object\n",
      "Conditions                     object\n",
      "Interventions                  object\n",
      "Primary Outcome Measures       object\n",
      "Secondary Outcome Measures     object\n",
      "Other Outcome Measures         object\n",
      "Sponsor                        object\n",
      "Collaborators                  object\n",
      "Sex                            object\n",
      "Age                            object\n",
      "Phases                         object\n",
      "Enrollment                      int64\n",
      "Funder Type                    object\n",
      "Study Type                     object\n",
      "Study Design                   object\n",
      "Other IDs                      object\n",
      "Start Date                     object\n",
      "Primary Completion Date        object\n",
      "Completion Date                object\n",
      "First Posted                   object\n",
      "Results First Posted          float64\n",
      "Last Update Posted             object\n",
      "Locations                      object\n",
      "Study Documents                object\n",
      "dtype: object\n"
     ]
    }
   ],
   "source": [
    "# Data types\n",
    "print(\"Data Types:\\n\", df_raw.dtypes)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "65c86c5a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Missing Values:\n",
      " NCT Number                       0\n",
      "Study Title                      0\n",
      "Study URL                        0\n",
      "Acronym                       4337\n",
      "Study Status                     0\n",
      "Brief Summary                    0\n",
      "Study Results                    0\n",
      "Conditions                       0\n",
      "Interventions                    0\n",
      "Primary Outcome Measures         0\n",
      "Secondary Outcome Measures     711\n",
      "Other Outcome Measures        5821\n",
      "Sponsor                          0\n",
      "Collaborators                 4435\n",
      "Sex                              0\n",
      "Age                              0\n",
      "Phases                           0\n",
      "Enrollment                       0\n",
      "Funder Type                      0\n",
      "Study Type                       0\n",
      "Study Design                     0\n",
      "Other IDs                        0\n",
      "Start Date                       0\n",
      "Primary Completion Date          0\n",
      "Completion Date                  1\n",
      "First Posted                     0\n",
      "Results First Posted          6676\n",
      "Last Update Posted               0\n",
      "Locations                      704\n",
      "Study Documents               6580\n",
      "dtype: int64\n"
     ]
    }
   ],
   "source": [
    "# Missing values\n",
    "print(\"Missing Values:\\n\",df_raw.isnull().sum())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "f7ed7d5f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Duplicates: 0\n"
     ]
    }
   ],
   "source": [
    "# Duplicate rows\n",
    "print(\"Duplicates:\", df_raw.duplicated().sum())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "5efdbaaf",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Unique Values per Column:\n",
      " NCT Number                    6676\n",
      "Study Title                   6673\n",
      "Study URL                     6676\n",
      "Acronym                       2265\n",
      "Study Status                     2\n",
      "Brief Summary                 6668\n",
      "Study Results                    1\n",
      "Conditions                    3842\n",
      "Interventions                 6284\n",
      "Primary Outcome Measures      6534\n",
      "Secondary Outcome Measures    5919\n",
      "Other Outcome Measures         851\n",
      "Sponsor                       2218\n",
      "Collaborators                 1456\n",
      "Sex                              3\n",
      "Age                              5\n",
      "Phases                           4\n",
      "Enrollment                     765\n",
      "Funder Type                      8\n",
      "Study Type                       1\n",
      "Study Design                   183\n",
      "Other IDs                     6673\n",
      "Start Date                    1915\n",
      "Primary Completion Date       1269\n",
      "Completion Date               1283\n",
      "First Posted                  1660\n",
      "Results First Posted             0\n",
      "Last Update Posted             857\n",
      "Locations                     4715\n",
      "Study Documents                 96\n",
      "dtype: int64\n"
     ]
    }
   ],
   "source": [
    "# Unique values per column\n",
    "print(\"Unique Values per Column:\\n\", df_raw.nunique())"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "78918f0b",
   "metadata": {},
   "source": [
    "### Cleaning data\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "03ce61f2",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Dropping irelevant columns\n",
    "columns_to_drop = [\n",
    "    'Study URL', 'Acronym', 'Study Results', 'Other Outcome Measures', \n",
    "    'Collaborators', 'Other IDs', 'First Posted', 'Results First Posted', \n",
    "    'Study Documents'\n",
    "]\n",
    "df = df.drop(columns=columns_to_drop)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "f080aa67",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(6676, 21)"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "c7e59b87",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "NCT Number                      0\n",
      "Study Title                     0\n",
      "Study Status                    0\n",
      "Brief Summary                   0\n",
      "Conditions                      0\n",
      "Interventions                   0\n",
      "Primary Outcome Measures        0\n",
      "Secondary Outcome Measures    711\n",
      "Sponsor                         0\n",
      "Sex                             0\n",
      "Age                             0\n",
      "Phases                          0\n",
      "Enrollment                      0\n",
      "Funder Type                     0\n",
      "Study Type                      0\n",
      "Study Design                    0\n",
      "Start Date                      0\n",
      "Primary Completion Date         0\n",
      "Completion Date                 1\n",
      "Last Update Posted              0\n",
      "Locations                     704\n",
      "dtype: int64\n"
     ]
    }
   ],
   "source": [
    "print(df.isnull().sum())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "3fd0415f",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Fill missing 'Secondary Outcome Measures'\n",
    "df['Secondary Outcome Measures'] = df['Secondary Outcome Measures'].fillna('Not specified')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "c44214c2",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Fill missing 'Locations'\n",
    "df['Locations'] = df['Locations'].fillna('Not specified')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "98c43cdd",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Convert 'Completion Date' and other date columns to datetime\n",
    "date_cols = ['Start Date', 'Primary Completion Date', 'Completion Date', 'Last Update Posted']\n",
    "for col in date_cols:\n",
    "    df[col] = pd.to_datetime(df[col], errors='coerce')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "id": "55e3ce96",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Add missing flags for date columns\n",
    "df['missing_start_date'] = df['Start Date'].isna().astype(int)\n",
    "df['missing_primary_completion_date'] = df['Primary Completion Date'].isna().astype(int)\n",
    "df['missing_completion_date'] = df['Completion Date'].isna().astype(int)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "id": "936353b5",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "study_title                           0\n",
      "study_status                          0\n",
      "brief_summary                         0\n",
      "conditions                            0\n",
      "interventions                         0\n",
      "primary_outcome_measures              0\n",
      "secondary_outcome_measures            0\n",
      "sponsor                               0\n",
      "enrollment                            0\n",
      "study_type                            0\n",
      "study_design                          0\n",
      "Start Date                          618\n",
      "Primary Completion Date            2180\n",
      "Completion Date                    2216\n",
      "last_update_posted                    0\n",
      "locations                             0\n",
      "study_duration_days                   0\n",
      "sex_all                               0\n",
      "sex_female                            0\n",
      "sex_male                              0\n",
      "has_child                             0\n",
      "has_adult                             0\n",
      "has_older_adult                       0\n",
      "phase1                                0\n",
      "phase2                                0\n",
      "phase3                                0\n",
      "funder_fed                            0\n",
      "funder_indiv                          0\n",
      "funder_industry                       0\n",
      "funder_network                        0\n",
      "funder_nih                            0\n",
      "funder_other                          0\n",
      "funder_other_gov                      0\n",
      "funder_unknown                        0\n",
      "missing_start_date                    0\n",
      "missing_primary_completion_date       0\n",
      "missing_completion_date               0\n",
      "dtype: int64\n"
     ]
    }
   ],
   "source": [
    "print(df.isnull().sum())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "5c0e4b5c",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Duration of the clinical trial (in days)\n",
    "df['study_duration_days'] = (df['Completion Date'] - df['Start Date']).dt.days"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "064e1c9a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "NCT Number                       0\n",
      "Study Title                      0\n",
      "Study Status                     0\n",
      "Brief Summary                    0\n",
      "Conditions                       0\n",
      "Interventions                    0\n",
      "Primary Outcome Measures         0\n",
      "Secondary Outcome Measures       0\n",
      "Sponsor                          0\n",
      "Sex                              0\n",
      "Age                              0\n",
      "Phases                           0\n",
      "Enrollment                       0\n",
      "Funder Type                      0\n",
      "Study Type                       0\n",
      "Study Design                     0\n",
      "Start Date                     618\n",
      "Primary Completion Date       2180\n",
      "Completion Date               2216\n",
      "Last Update Posted               0\n",
      "Locations                        0\n",
      "study_duration_days           2253\n",
      "dtype: int64\n"
     ]
    }
   ],
   "source": [
    "print(df.isnull().sum())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "86b19b76",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Impute missing durations \n",
    "median_duration = df['study_duration_days'].median()\n",
    "df['study_duration_days'] = df['study_duration_days'].fillna(median_duration)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "id": "a975d3ab",
   "metadata": {},
   "outputs": [],
   "source": [
    "df = df.drop(columns=['Start Date', 'Primary Completion Date', 'Completion Date'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "id": "af9b992e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "study_title                        0\n",
      "study_status                       0\n",
      "brief_summary                      0\n",
      "conditions                         0\n",
      "interventions                      0\n",
      "primary_outcome_measures           0\n",
      "secondary_outcome_measures         0\n",
      "sponsor                            0\n",
      "enrollment                         0\n",
      "study_type                         0\n",
      "study_design                       0\n",
      "last_update_posted                 0\n",
      "locations                          0\n",
      "study_duration_days                0\n",
      "sex_all                            0\n",
      "sex_female                         0\n",
      "sex_male                           0\n",
      "has_child                          0\n",
      "has_adult                          0\n",
      "has_older_adult                    0\n",
      "phase1                             0\n",
      "phase2                             0\n",
      "phase3                             0\n",
      "funder_fed                         0\n",
      "funder_indiv                       0\n",
      "funder_industry                    0\n",
      "funder_network                     0\n",
      "funder_nih                         0\n",
      "funder_other                       0\n",
      "funder_other_gov                   0\n",
      "funder_unknown                     0\n",
      "missing_start_date                 0\n",
      "missing_primary_completion_date    0\n",
      "missing_completion_date            0\n",
      "dtype: int64\n"
     ]
    }
   ],
   "source": [
    "print(df.isnull().sum())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "ecd6e099",
   "metadata": {},
   "outputs": [],
   "source": [
    "df = df.set_index('NCT Number')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "2423962f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Study Title                           object\n",
      "Study Status                          object\n",
      "Brief Summary                         object\n",
      "Conditions                            object\n",
      "Interventions                         object\n",
      "Primary Outcome Measures              object\n",
      "Secondary Outcome Measures            object\n",
      "Sponsor                               object\n",
      "Sex                                   object\n",
      "Age                                   object\n",
      "Phases                                object\n",
      "Enrollment                             int64\n",
      "Funder Type                           object\n",
      "Study Type                            object\n",
      "Study Design                          object\n",
      "Start Date                    datetime64[ns]\n",
      "Primary Completion Date       datetime64[ns]\n",
      "Completion Date               datetime64[ns]\n",
      "Last Update Posted            datetime64[ns]\n",
      "Locations                             object\n",
      "study_duration_days                  float64\n",
      "dtype: object\n"
     ]
    }
   ],
   "source": [
    "print(df.dtypes)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "8ce1cca2",
   "metadata": {},
   "outputs": [],
   "source": [
    "categorical_cols = [\n",
    "    'Study Title', 'Study Status', 'Brief Summary', 'Conditions', 'Interventions', \n",
    "    'Primary Outcome Measures', 'Secondary Outcome Measures', 'Sponsor', 'Sex', 'Age', \n",
    "    'Phases', 'Funder Type', 'Study Type', 'Study Design', 'Locations'\n",
    "]\n",
    "\n",
    "for col in categorical_cols:\n",
    "    df[col] = df[col].astype('category')\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "23747937",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Study Status\n",
      "RECRUITING            5147\n",
      "NOT_YET_RECRUITING    1529\n",
      "Name: count, dtype: int64\n"
     ]
    }
   ],
   "source": [
    "print(df['Study Status'].value_counts())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "00fc153a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sex\n",
      "ALL       5520\n",
      "FEMALE     803\n",
      "MALE       353\n",
      "Name: count, dtype: int64\n",
      "Age\n",
      "ADULT, OLDER_ADULT           6136\n",
      "CHILD, ADULT, OLDER_ADULT     261\n",
      "CHILD, ADULT                  144\n",
      "ADULT                          88\n",
      "OLDER_ADULT                    47\n",
      "Name: count, dtype: int64\n",
      "Phases\n",
      "PHASE2           3508\n",
      "PHASE3           1503\n",
      "PHASE1|PHASE2    1396\n",
      "PHASE2|PHASE3     269\n",
      "Name: count, dtype: int64\n",
      "Funder Type\n",
      "OTHER        4472\n",
      "INDUSTRY     1841\n",
      "OTHER_GOV     140\n",
      "NIH           105\n",
      "NETWORK        90\n",
      "FED            25\n",
      "UNKNOWN         2\n",
      "INDIV           1\n",
      "Name: count, dtype: int64\n",
      "Study Type\n",
      "INTERVENTIONAL    6676\n",
      "Name: count, dtype: int64\n",
      "Study Design\n",
      "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT                                                                           2168\n",
      "Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT                                                                       1456\n",
      "Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT                                                                    426\n",
      "Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT     421\n",
      "Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT                                                                  367\n",
      "                                                                                                                                                                   ... \n",
      "Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT                      1\n",
      "Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE                                                   1\n",
      "Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE                                                     1\n",
      "Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION                                                  1\n",
      "Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT                                                      1\n",
      "Name: count, Length: 183, dtype: int64\n",
      "Locations\n",
      "Not specified                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        704\n",
      "M D Anderson Cancer Center, Houston, Texas, 77030, United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      63\n",
      "National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               60\n",
      "Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 200032, China                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            57\n",
      "Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, China                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             37\n",
      "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ... \n",
      "Henan Provincial Cancer Hospital, Zhengzhou, Henan, 450000, China                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1\n",
      "Henan Provincial People's Hospital, Zhengzhou, Henan, China|Hubei Cancer Hospital, Wuhan, Hubei, China|The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, China|the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China|Shandong Cancer Hospital & Institute, Jinan, Shandong, China|Sichuan Cancer Hospital, Chengdu, Sichuan, China|Sichuan Provincial People's Hospital, Chengdu, Sichuan, China|Ningbo No.2 Hospital, Ningbo, Zhejiang, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China      1\n",
      "Henan Tumor Hospital, Zhengzhou, Henan, 450000, China                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  1\n",
      "HenanCH, Zhengzhou, Henan, 450000, China                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               1\n",
      "Âåó‰∫¨È´òÂçöÂåªÈô¢, Âåó‰∫¨, Âåó‰∫¨Â∏ÇÊòåÂπ≥Âå∫, 102200, China                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1\n",
      "Name: count, Length: 4716, dtype: int64\n"
     ]
    }
   ],
   "source": [
    "print(df['Sex'].value_counts())\n",
    "print(df['Age'].value_counts())\n",
    "print(df['Phases'].value_counts())\n",
    "print(df['Funder Type'].value_counts())\n",
    "print(df['Study Type'].value_counts())\n",
    "print(df['Study Design'].value_counts())\n",
    "print(df['Locations'].value_counts())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "2e071b66",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Study Status\n",
      "1    5147\n",
      "0    1529\n",
      "Name: count, dtype: int64\n"
     ]
    }
   ],
   "source": [
    "df['Study Status'] = df['Study Status'].map({'RECRUITING': 1, 'NOT_YET_RECRUITING': 0})\n",
    "print(df['Study Status'].value_counts())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "0ac63237",
   "metadata": {},
   "outputs": [],
   "source": [
    "sex_dummies = pd.get_dummies(df['Sex'], prefix='Sex')\n",
    "df = pd.concat([df, sex_dummies], axis=1)\n",
    "df.drop('Sex', axis=1, inplace=True)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "a0729a2e",
   "metadata": {},
   "outputs": [],
   "source": [
    "df['has_child'] = df['Age'].apply(lambda x: 1 if 'CHILD' in x else 0)\n",
    "df['has_adult'] = df['Age'].apply(lambda x: 1 if 'ADULT' in x else 0)\n",
    "df['has_older_adult'] = df['Age'].apply(lambda x: 1 if 'OLDER_ADULT' in x else 0)\n",
    "df.drop('Age', axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "a681ab51",
   "metadata": {},
   "outputs": [],
   "source": [
    "df['Phase1'] = df['Phases'].apply(lambda x: 1 if 'PHASE1' in x else 0)\n",
    "df['Phase2'] = df['Phases'].apply(lambda x: 1 if 'PHASE2' in x else 0)\n",
    "df['Phase3'] = df['Phases'].apply(lambda x: 1 if 'PHASE3' in x else 0)\n",
    "df.drop('Phases', axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "3ce6b547",
   "metadata": {},
   "outputs": [],
   "source": [
    "funder_dummies = pd.get_dummies(df['Funder Type'], prefix='Funder')\n",
    "df = pd.concat([df, funder_dummies], axis=1)\n",
    "df.drop('Funder Type', axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "ccaa1764",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['Study Title', 'Study Status', 'Brief Summary', 'Conditions',\n",
       "       'Interventions', 'Primary Outcome Measures',\n",
       "       'Secondary Outcome Measures', 'Sponsor', 'Enrollment', 'Study Type',\n",
       "       'Study Design', 'Start Date', 'Primary Completion Date',\n",
       "       'Completion Date', 'Last Update Posted', 'Locations',\n",
       "       'study_duration_days', 'Sex_ALL', 'Sex_FEMALE', 'Sex_MALE', 'has_child',\n",
       "       'has_adult', 'has_older_adult', 'Phase1', 'Phase2', 'Phase3',\n",
       "       'Funder_FED', 'Funder_INDIV', 'Funder_INDUSTRY', 'Funder_NETWORK',\n",
       "       'Funder_NIH', 'Funder_OTHER', 'Funder_OTHER_GOV', 'Funder_UNKNOWN'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "id": "c483ccee",
   "metadata": {},
   "outputs": [],
   "source": [
    "rename_dict = {\n",
    "    'Study Title': 'study_title',\n",
    "    'Study Status': 'study_status',\n",
    "    'Brief Summary': 'brief_summary',\n",
    "    'Conditions': 'conditions',\n",
    "    'Interventions': 'interventions',\n",
    "    'Primary Outcome Measures': 'primary_outcome_measures',\n",
    "    'Secondary Outcome Measures': 'secondary_outcome_measures',\n",
    "    'Sponsor': 'sponsor',\n",
    "    'Enrollment': 'enrollment',\n",
    "    'Study Type': 'study_type',\n",
    "    'Study Design': 'study_design',\n",
    "    'Last Update Posted': 'last_update_posted',\n",
    "    'Locations': 'locations',\n",
    "    'study_duration_days': 'study_duration_days',\n",
    "    'Sex_ALL': 'sex_all',\n",
    "    'Sex_FEMALE': 'sex_female',\n",
    "    'Sex_MALE': 'sex_male',\n",
    "    'has_child': 'has_child',\n",
    "    'has_adult': 'has_adult',\n",
    "    'has_older_adult': 'has_older_adult',\n",
    "    'Phase1': 'phase1',\n",
    "    'Phase2': 'phase2',\n",
    "    'Phase3': 'phase3',\n",
    "    'Funder_FED': 'funder_fed',\n",
    "    'Funder_INDIV': 'funder_indiv',\n",
    "    'Funder_INDUSTRY': 'funder_industry',\n",
    "    'Funder_NETWORK': 'funder_network',\n",
    "    'Funder_NIH': 'funder_nih',\n",
    "    'Funder_OTHER': 'funder_other',\n",
    "    'Funder_OTHER_GOV': 'funder_other_gov',\n",
    "    'Funder_UNKNOWN': 'funder_unknown'\n",
    "}\n",
    "\n",
    "df = df.rename(columns=rename_dict)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "0d046647",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['study_title', 'study_status', 'brief_summary', 'conditions',\n",
       "       'interventions', 'primary_outcome_measures',\n",
       "       'secondary_outcome_measures', 'sponsor', 'enrollment', 'study_type',\n",
       "       'study_design', 'Start Date', 'Primary Completion Date',\n",
       "       'Completion Date', 'last_update_posted', 'locations',\n",
       "       'study_duration_days', 'sex_all', 'sex_female', 'sex_male', 'has_child',\n",
       "       'has_adult', 'has_older_adult', 'phase1', 'phase2', 'phase3',\n",
       "       'funder_fed', 'funder_indiv', 'funder_industry', 'funder_network',\n",
       "       'funder_nih', 'funder_other', 'funder_other_gov', 'funder_unknown'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "c566b285",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "Index: 6676 entries, NCT06767735 to NCT06947460\n",
      "Data columns (total 34 columns):\n",
      " #   Column                      Non-Null Count  Dtype         \n",
      "---  ------                      --------------  -----         \n",
      " 0   study_title                 6676 non-null   category      \n",
      " 1   study_status                6676 non-null   category      \n",
      " 2   brief_summary               6676 non-null   category      \n",
      " 3   conditions                  6676 non-null   category      \n",
      " 4   interventions               6676 non-null   category      \n",
      " 5   primary_outcome_measures    6676 non-null   category      \n",
      " 6   secondary_outcome_measures  6676 non-null   category      \n",
      " 7   sponsor                     6676 non-null   category      \n",
      " 8   enrollment                  6676 non-null   int64         \n",
      " 9   study_type                  6676 non-null   category      \n",
      " 10  study_design                6676 non-null   category      \n",
      " 11  Start Date                  6058 non-null   datetime64[ns]\n",
      " 12  Primary Completion Date     4496 non-null   datetime64[ns]\n",
      " 13  Completion Date             4460 non-null   datetime64[ns]\n",
      " 14  last_update_posted          6676 non-null   datetime64[ns]\n",
      " 15  locations                   6676 non-null   category      \n",
      " 16  study_duration_days         6676 non-null   float64       \n",
      " 17  sex_all                     6676 non-null   bool          \n",
      " 18  sex_female                  6676 non-null   bool          \n",
      " 19  sex_male                    6676 non-null   bool          \n",
      " 20  has_child                   6676 non-null   int64         \n",
      " 21  has_adult                   6676 non-null   int64         \n",
      " 22  has_older_adult             6676 non-null   int64         \n",
      " 23  phase1                      6676 non-null   int64         \n",
      " 24  phase2                      6676 non-null   int64         \n",
      " 25  phase3                      6676 non-null   int64         \n",
      " 26  funder_fed                  6676 non-null   bool          \n",
      " 27  funder_indiv                6676 non-null   bool          \n",
      " 28  funder_industry             6676 non-null   bool          \n",
      " 29  funder_network              6676 non-null   bool          \n",
      " 30  funder_nih                  6676 non-null   bool          \n",
      " 31  funder_other                6676 non-null   bool          \n",
      " 32  funder_other_gov            6676 non-null   bool          \n",
      " 33  funder_unknown              6676 non-null   bool          \n",
      "dtypes: bool(11), category(11), datetime64[ns](4), float64(1), int64(7)\n",
      "memory usage: 2.5+ MB\n"
     ]
    }
   ],
   "source": [
    "df.info()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 119,
   "id": "4b3d47f1",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Value counts for 'study_title':\n",
      "study_title\n",
      "A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors                                                                                                                                                              3\n",
      "Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM                                                                                                                                                                      2\n",
      "\"Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Beh√ßet's Disease\"                                                                                                                                     1\n",
      "Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women with Triple-negative Breast Cancer                                                                                                                                               1\n",
      "Percutaneous Embolectomy, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism                                                                                                                                    1\n",
      "                                                                                                                                                                                                                                                      ..\n",
      "Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Minor Stroke or TIA                                                                                                                                                  1\n",
      "Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer                                                                                                                                                                1\n",
      "Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer                                                                                                                                                             1\n",
      "Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH)                                                                                                                                                1\n",
      "to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)    1\n",
      "Name: count, Length: 6673, dtype: int64\n",
      "\n",
      "Value counts for 'study_status':\n",
      "study_status\n",
      "1    5147\n",
      "0    1529\n",
      "Name: count, dtype: int64\n",
      "\n",
      "Value counts for 'brief_summary':\n",
      "brief_summary\n",
      "This study is a prospective, open-label, phase II clinical study for patients with HR+/HER2- advanced breast cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              3\n",
      "The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      2\n",
      "This study aims to evaluate the efficacy of Y-6 sublingual tablets in improving microcirculation dysfunction and reducing thrombo-inflammation in patients who had AIS caused by LVO and received reperfusion therapy. Moreover, we expect to evaluate the safety of using Y-6 sublingual tablet in such study population.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        2\n",
      "The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          2\n",
      "This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CEA-positive advanced malignant tumors. The pharmacokinetic characteristics of CAR-T cell preparations for the treatment of patients with CEA-positive advanced malignancies were obtained and the recommended dose and infusion schedule.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            2\n",
      "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ..\n",
      "The extent of breast cancer is an important prognostic factor in patients diagnosed with this disease. Therefore, adequate staging at diagnosis is a requisite for optimal treatment. In all patients diagnosed with locally advanced breast cancer (LABC), distant staging using 18F-FDG PET/CT is recommended. However, the degree of metabolic uptake in the primary breast tumor is significantly lower in the ER+ subtype compared to HER2+ and triple negative breast cancer (TNBC). As a consequence, a suboptimal 18F-FDG uptake in ER+ breast cancer patients can potentially lead to missed distant metastases. Fibroblast-activating protein inhibitor (FAPI) is a recently developed radiotracer that binds to FAP, a stromal antigen overexpressed in more than 90% of epithelial-derived tumors and their metastases. Previous studies all show 68Ga-FAPI PET/CT to have a higher detection rate compared to 18F-FDG PET/CT. However, all previous studies were performed without considering breast cancer subtype. If the metabolic uptake by 68Ga-FAPI-46 is higher in ER+ breast cancer patients, more lesions will be detected, resulting in a more appropriate treatment for these patients. Therefore, in this pilot study, the investigators aim to compare the diagnostic performance of 18F-FDG with 68Ga-FAPI-46 as PET-tracer in ER+ breast cancer patients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            1\n",
      "The evidence-based pharmacologic treatments available for patients with heart failure with reduced ejection fraction (HFrEF) has been established over the last few decades of cardiovascular research. These treatments, termed Foundational Guideline-Directed-Medical Therapies (GDMT), prolong patient life, improve patient-reported symptoms, and reduce hospitalizations for heart failure. A direct effect of most medication classes encompassed within GDMT is the reduction in blood pressure due to their mechanisms of action. In addition, as patients with HFrEF become more advanced in their disease, a significant proportion develop hypotension related to pump failure and autonomic dysfunction, amongst other possible mechanisms. As a result, a significant proportion of HFrEF patients are not optimized on GDMT with hypotension as their limiting barrier that would otherwise have served to improve their heart function, heart failure symptoms, and mortality. Currently, there does not exist any evidence-based strategies to address the problem of hypotension in HFrEF patients who are not optimized on GDMT.\\n\\nMidodrine is an alpha-adrenergic agonist (Œ±1-AR) that exerts its effects on peripheral venous and arteriolar vasculature to increase blood pressure. This medication has been used off-label by some clinicians in the hypotensive HFrEF population to increase blood pressure and has been reported to have beneficial effects in improving GDMT utilization as well as increasing left ventricular ejection fraction (LVEF) in published case reports/case series. There does not exist any randomized prospective data on the use of midodrine in the hypotensive HFrEF population. The investigators' objective is to complete the first open-label, randomized control trial of midodrine in the hypotensive HFrEF population to demonstrate feasibility in performing a trial in this patient population and to show efficacy in increasing blood pressure without associated harm. The results of this trial will be used as the foundation and rationale for future studies assessing the impact of midodrine use on GDMT utilization as well as hard cardiovascular outcomes in the hypotensive HFrEF population, including hospitalizations for heart failure and mortality.    1\n",
      "The evidence supporting routine provision of high-dose, high-intensity upper limb neurorehabilitation treatment for stroke survivors beyond the first few months after stroke is limited. The Queen Square Upper Limb (QSUL) programme provides 90 hours of upper limb neurorehabilitation over 3-weeks to chronic stroke survivors. The recently published service evaluation demonstrated encouragingly large, clinically meaningful effects at the level of activity and body function. An alternative way to deliver high doses of effective therapy is through technological developments, e.g. immersive interactive gaming environments such as the MindPod Dolphin programme.\\n\\nThe intention of this study is to provide stronger level evidence for intensive upper limb rehabilitation by conducting a randomised controlled trial of two different types of upper limb training compared to usual care. Patients considered suitable for the QSUL programme will be randomised to either: Group 1- intensive upper limb rehabilitation programme (QSUL); Group 2- MindPod programme; Group 3-wait-list control (who will be offered the treatment after the waiting list is complete).\\n\\nThe first aim of the study is to compare the effect of each type of high-dose, high-intensity upper limb training to usual care using measures of upper limb impairment and activity levels 3 months after treatment is complete.\\n\\nThe secondary aims are to comply with recent recommended by the Stroke Recovery and Rehabilitation Roundtable, and (i) investigate the effects of upper limb neurorehabilitation on kinematics of upper limb movement (using a KINARM exoskeleton), and (ii) use neuroimaging (MRI and EEG) and neurophysiological (TMS) measures to determine the characteristics of stroke survivors who are most likely to benefit from this treatment approach.\\n\\nThe results from this work will (i) help determine the impact of two methods of high dose, high intensity upper limb training in chronic stroke patients; (ii) identify whether there are any predictors of treatment response that will help stratify patients in future clinical trials of upper limb neurorehabilitation.                                                                                                                   1\n",
      "The efficacy of treatment with metformin for promoting cognitive recovery and brain growth in children/adolescents treated for medulloblastoma will be investigated in a multi-site Phase III randomized double-blind placebo-controlled parallel arm superiority trial. Specifically, in children/adolescents aged 7 years to 17 years and 11 months who have completed treatment for medulloblastoma, is oral administration of metformin for 16 weeks associated with greater improvement of cognitive function and brain growth compared to placebo administered for 16 weeks?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                1\n",
      "‚ñ™ Fulvestrant With Ribociclib versus Physician's choice treatments for the patients who recurred after completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer as first line treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               1\n",
      "Name: count, Length: 6668, dtype: int64\n",
      "\n",
      "Value counts for 'conditions':\n",
      "conditions\n",
      "Breast Cancer                                                                                                                                                                                                     196\n",
      "Multiple Myeloma                                                                                                                                                                                                  117\n",
      "Prostate Cancer                                                                                                                                                                                                   116\n",
      "Non-small Cell Lung Cancer                                                                                                                                                                                        104\n",
      "Advanced Solid Tumor                                                                                                                                                                                               76\n",
      "                                                                                                                                                                                                                 ... \n",
      "Extramedullary Disease in Multiple Myeloma|Multiple Myeloma                                                                                                                                                         1\n",
      "Extramedullary Disease in Multiple Myeloma|Recurrent Multiple Myeloma|Refractory Multiple Myeloma                                                                                                                   1\n",
      "Eye Cancer|Metastatic Breast Cancer|Lung Cancer                                                                                                                                                                     1\n",
      "FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma|FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma|Metastatic Endometrial Endometrioid Adenocarcinoma|Recurrent Endometrial Endometrioid Adenocarcinoma      1\n",
      "type1diabetes|Diabetes Mellitus, Type 1                                                                                                                                                                             1\n",
      "Name: count, Length: 3842, dtype: int64\n",
      "\n",
      "Value counts for 'interventions':\n",
      "interventions\n",
      "DRUG: Pembrolizumab                                                                     14\n",
      "DRUG: Metformin                                                                         12\n",
      "DRUG: Colchicine|DRUG: Placebo                                                           8\n",
      "DRUG: Pembrolizumab|DRUG: Lenvatinib                                                     7\n",
      "DRUG: Sacituzumab govitecan                                                              7\n",
      "                                                                                        ..\n",
      "DRUG: Dexamethasone|DRUG: Placebo                                                        1\n",
      "DRUG: Dexamethasone|DRUG: Leflunomide|DRUG: Pomalidomide                                 1\n",
      "DRUG: Dexamethasone|DRUG: Isatuximab|DRUG: Lenalidomide                                  1\n",
      "DRUG: Dexamethasone|DRUG: Iberdomide Hydrochloride|OTHER: Quality-of-Life Assessment     1\n",
      "RADIATION: stereotactic radiation therapy in ablative doses to each metastatic site      1\n",
      "Name: count, Length: 6284, dtype: int64\n",
      "\n",
      "Value counts for 'primary_outcome_measures':\n",
      "primary_outcome_measures\n",
      "Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0, through study completion; an average of 1 year.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    7\n",
      "Safety and Adverse Events (AEs), Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0, Through study completion; an average of 1 year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    7\n",
      "Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0, through study completion; an average of 1 year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     6\n",
      "Safety and adverse events (AEs), Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0, Through study completion; an average of 1 year.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   6\n",
      "rate of new stroke, Rates of new stroke occur within three months of treatment. The investigators will perform follow-ups of the patient during visits to the outpatient clinic, and brain CT and/ or MRI will be done if there is suspicion of a new stroke., 90 days|Rate of drug-related hemorrhagic complications, the rate of drug hemorrhagic complications which was evaluated using the PLATO bleeding definition which classified hemorrhagic complications into three types as follows: Major bleeding which had one or more of the following criteria: fatal bleeding, intracranial, intrapericardial, bleeding associated with reduction of hemoglobin \\> 3-5 g/dl, bleeding required transfusion of two to four units whole blood or PRBCs, bleeding produced hypovolemic shock or severe hypotension that required pressor or surgery; Minor bleeding that required medical intervention to stop or treat bleeding: Minimal bleeding: any bleeding that did not require intervention or treatment such as bruising, bleeding gums, oozing from injection sites., 90 days    6\n",
      "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ..\n",
      "Local progression-free survival, Local progression-free survival was defined from the start of carbon ion radiotherapy till the date of local progression or the last follow-up, From date of radiotherapy started until the date of first documented local disease progression, assessed up to 100 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                1\n",
      "Local progression free survival, Progression is determined using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. criteria, compared to the scan immediately prior to treatment of that territory, using the 2 largest measurable lesions per treated territory. Local progression-free survival will be estimated using the Kaplan-Meier method., Time from the initial transarterial chemoembolization (TACE) treatment to progression in a completely treated territory (or touching the border of a completely treated area), or death from any cause, assessed at 6 months|Incidence of adverse events, Complications will be classified using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The rate of complications can be estimated with a standard error of less than 10%. Further, any complication that occurs with a 10% incidence will be observed with greater than 95% probability., Up to 3 months after the last chemoembolization procedure                                                              1\n",
      "Local objective response rate, the proportion of patients with the best pelvic response of confirmed complete or partial response according to RECIST 1.1, as assessed by the investigator., up to 1 year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 1\n",
      "Local failure rate, The time from diagnostic biopsy to documented progression of intrathoracic disease as assessed by CT or X-ray imaging., The local failure rate will be assessed at the time point of 24 months.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       1\n",
      "‚àÜInfarct size/Left Ventricular mass%, Difference in Infarct size/Left ventricular mass% from baseline to 3 months after Nivolumab administration., 3 months|The incidence of adverse events, The incidence of adverse events during 3 months after Nivolumab treatment., up to 3 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   1\n",
      "Name: count, Length: 6534, dtype: int64\n",
      "\n",
      "Value counts for 'secondary_outcome_measures':\n",
      "secondary_outcome_measures\n",
      "Not specified                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             711\n",
      "Progression-free survival (PFS), The PFS is defined as the time from the first dose of medication to disease progression or death, whichever occurred first., Up to approximately 24 months|Disease control rate (DCR), The DCR is defined as the percentage of participants who has a CR, PR, or Stable Disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \\[PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD\\])., Up to approximately 24 months|Duration of response (DOR), The DOR for a responder is defined as the time from the participant's initial objective response to the first date of either disease progression or death, whichever occurs first., Up to approximately 24 months|Treatment-Emergent Adverse Event (TEAE), TEAE is defined as any adverse and unexpected change in body structure, function, or chemistry or any exacerbation of an existing condition (i.e., any clinically significant adverse change in frequency and/or intensity) during treatment. The type, frequency, and severity of TEAE will be assessed during treatment., Up to approximately 24 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      6\n",
      "Objective Response Rate (ORR), Proportion of patients with response per Response Evaluation Criteria in Solid Tumors, Up to 36 months|Disease Control Rate (DCRÔºâ, Percentage of patients that meet CR, PR and SD criteria set in this study, Up to 36 months|Duration of Response (DOR), The time length between the first confirmed objective response to the treatment and the subsequent disease progression, Up to 36 months|Progression-Free Survival (PFS), The time length between TIL infusion and confirmed subsequent disease progression, Up to 36 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        5\n",
      "Overall survival, Overall survival (OS) will be defined as the elapsed time from the enrollment to death from any cause. For surviving patients, follow-up will be censored at the date of last contact (or last date known to be alive). Follow-up for OS will occur every 12 weeks (¬±1 month) until death or withdrawal of consent from the study., 5 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               4\n",
      "overall response rate (ORR), Assessment of ORR at Month 6, 12, 18 and 24, Month 6, 12, 18 and 24|complete response (CR), Assessment of CR at Month 6, 12, 18 and 24, Month 6, 12, 18 and 24|Overall survival (OS), Assessment of OS at Month 6, 12, 18 and 24, Month 6, 12, 18 and 24|Event-free survival (EFS), Assessment of EFS at Month 6, 12, 18 and 24, Month 6, 12, 18 and 24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        3\n",
      "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ... \n",
      "Interim efficacy: Mutational burden as assessed by change in variant allele frequency, Change in variant allele frequency (ŒîVAF) by next generation sequencing (NGS), From inclusion to 12 months of study treatment|Interim efficacy: Patient-reported outcome measures based on the EORTC QLQ-C30, Change in patient-reported outcome measures (PROM), based on the validated European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)., From inclusion to 4 months of study treatment|Interim efficacy: Patient-reported outcome measures based on the EORTC QLQ-C30, Change in patient-reported outcome measures (PROM), based on the validated European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)., From inclusion to 12 months of study treatment|Interim efficacy: Patient-reported outcome measures based on the SF-36, Change in patient-reported outcome measures (PROM), based on the validated Short Form 36 Health Survey Questionnaire (SF-36)., From inclusion to 4 months of study treatment|Interim efficacy: Patient-reported outcome measures based on the SF-36, Change in patient-reported outcome measures (PROM), based on the validated Short Form 36 Health Survey Questionnaire (SF-36)., From inclusion to 12 months of study treatment|Interim efficacy: Patient-reported outcome measures based on the EQ-5D, Change in patient-reported outcome measures (PROM), based on the validated European Quality of Life Five Dimension questionnaire (EQ-5D)., From inclusion to 4 months of study treatment|Interim efficacy: Patient-reported outcome measures based on the EQ-5D, Change in patient-reported outcome measures (PROM), based on the validated European Quality of Life Five Dimension questionnaire (EQ-5D)., From inclusion to 12 months of study treatment|Interim efficacy: Bone marrow adipose tissue as assessed by MR spectroscopy ratio of adipose tissue and water phase, Change in bone marrow adipose tissue (BMAT) content in bone marrow (BM) measured by MR spectroscopy, From inclusion to 4 months of study treatment|Interim efficacy: Bone marrow adipose tissue as assessed by MR spectroscopy ratio of adipose tissue and water phase, Change in bone marrow adipose tissue (BMAT) content in bone marrow (BM) measured by MR spectroscopy, From inclusion to 12 months of study treatment|Interim efficacy: Bone mineral density as assessed by DEXA scan measured in grams per cubic centimeter with resulting Z score, Change in bone mineral density (BMD) measured by DEXA scan measured in grams per cubic centimeter with resulting Z score., From inclusion to 12 months of study treatment|Interim efficacy: Body composition as assessed by DEXA scan presented as whole body bone mass and soft tissue composition, Change in body composition measured by DEXA scan presented as whole body bone mass and soft tissue composition with ratios of lean mass, body fat, and bone mass., From inclusion to 12 months of study treatment|Interim efficacy: Gut microbiota composition as assessed by 16S rRNA sequencing, Change in gut microbiota by 16S rRNA sequencing or whole genome sequencing of intestinal bacteria., From inclusion to 4 months of study treatment|Interim efficacy: Gut microbiota composition as assessed by 16S rRNA sequencing, Change in gut microbiota by 16S rRNA sequencing or whole genome sequencing of intestinal bacteria., From inclusion to 12 months of study treatment|Interim efficacy: Small intestinal permeability as assessed by urine-lactulose/mannitol measurement and ion chromatography, Change in small intestinal permeability by functional assessment by urine-lactulose/mannitol measurement and ion chromatography or by indirect assessment by qPCR and 16S rRNA sequencing of whole blood., From inclusion to 4 months of study treatment|Interim efficacy: Epigenetic regulation as assessed by levels of 5-mC and 5-hmC, Change in DNA methylation and hydroxymethylation (5-mC and 5-hmC) patterns in hematopoietic cells by global 5-hmC/5-mC assessment and EPIC arrays., From inclusion to 4 months of study treatment|Interim efficacy: Epigenetic regulation as assessed by levels of 5-mC and 5-hmC, Change in DNA methylation and hydroxymethylation (5-mC and 5-hmC) patterns in hematopoietic cells by global 5-hmC/5-mC assessment and EPIC arrays., From inclusion to 12 months of study treatment|Interim efficacy: Gene expression as assessed by RNA sequencing, Change in RNA expression in hematopoietic cells and BM adipocytes., From inclusion to 4 months of study treatment|Interim efficacy: Gene expression as assessed by RNA sequencing, Change in RNA expression in hematopoietic cells and BM adipocytes., From inclusion to 12 months of study treatment|Interim efficacy: Protein profiles as assessed by proteomics, Change in protein profiles in hematopoietic cells and BM adipocytes by proteomics., From inclusion to 4 months of study treatment|Interim efficacy: Protein profiles as assessed by proteomics, Change in protein profiles in hematopoietic cells and BM adipocytes by proteomics., From inclusion to 12 months of study treatment|Interim efficacy: Response and disease progression as according to the IWG response criteria in myelodysplastic neoplasms, Rates of response and disease progression as according to the International Working Group (IWG) response criteria in myelodysplastic neoplasms., From inclusion to 12 months of study treatment|Interim efficacy: Bone marrow niche factor levels as assessed by ELISA, Change in niche factors in bone marrow by ELISA., From inclusion to 4 months of study treatment|Interim efficacy: Bone marrow niche factor levels as assessed by ELISA, Change in niche factors in bone marrow by ELISA., From inclusion to 12 months of study treatment|Interim efficacy: Cytokine levels as assessed by ELISA, Change in cytokine levels in peripheral blood and bone marrow plasma by ELISA., From inclusion to 4 months of study treatment|Interim efficacy: Cytokine levels as assessed by ELISA, Change in cytokine levels in peripheral blood and bone marrow plasma by ELISA., From inclusion to 12 months of study treatment      1\n",
      "Inter-reader reliability (IRR) for I-124 PET, Three blinded readers will interpret the non-investigational, usual care I-123 imaging and the I-124 imaging. A Cohen's Kappa will be used to measure the inter-reader variability for I-124 and I-123 separately. Kappa statistics range from -1 to 1 with higher values correspond to higher inter-rater reliability., 1 day|Proportion of participants with treatment-related adverse events, Proportion of participants with treatment-related adverse events, as classified and graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 5.0, Up to 5 days|Proportion of participants with positive I-124 PET in the overall population, The participant level detection rate will be assessed by calculating the number of participants interpreted as having a positive I-124 PET divided by the total number of participants with a scan evaluated by a reader., 1 day|Proportion of participants with positive I-124 PET in participants who have negative I-123 SPECT, In the subset of participants where the consensus read of the I-123 imaging study was negative, then the participant level detection rate for this population will be determined. The detection rate will be assessed by calculating the number of participants interpreted as having a positive I-124 PET divided by the total number of participants with a negative I-123 SPECT scan evaluated by a reader., 1 day|The proportion of lesions characterized as positive on I-124 PET and 24 hour I-123 SPECT, The total number of lesions detected for each participant using I-124 and I-123 (with a maximum of 10 lesions per region) will be compared and the proportion of all participants with lesions characterized by a consensus read as positive on both on I-124 PET and positive on 24 hour I-123 SPECT., 1 day|Proportion of lesions characterized as positive on both I-124 PET and 7-day post I-131, The total number of lesions detected for each participant using I-124 and I-123 (with a maximum of 10 lesions per region) will be compared and the proportion of all participants with lesions characterized by a consensus read as positive on both on I-124 PET and positive on 7-day post I-131 imaging, 1 day                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     1\n",
      "Inter-reader and intra-reader agreement of copper Cu 64 PSMA I&T PET/CT interpretation on a per-patient basis, Reader kappa statistics of copper Cu 64 PSMA I\\&T PET/CT scan interpretation by the blinded independent readers., 4 Hours|Incidence of adverse events in copper Cu 64 PSMA I&T injection, Treatment-emergent adverse events (AEs) will be assessed and graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0., At time of dose administration up to 72 Hours                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   1\n",
      "Intensity of fluorescence, To assess the intensity of fluorescence in malignant and non-malignant tissue, using quantifiable images, 7 days|Intensity of radiosignal, To assess the intensity of the radiosignal in malignant and non-malignant tissue, using radioactive measuring device., 7 days|Concordance between CEA and tracer, To assess the concordance between localization of the \\[111In\\]In-ANTI-CEA and CEA expression in rectal or pancreatic cancer and non-malignant tissue, by analyzing pathologic tissue for tracer activity and CEA presentation, 7 days|Blood levels of the dual-labeled antibody, To determine blood concentrations at several time points in patients to assess the pharmacokinetics of the tracer., 30, 60, 120, 180 minutes|Biodistribution, To determine the whole body biodistribution of the tracer over time by quantified SPECT/CT imaging at 2 timepoints., 7 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         1\n",
      "‚àÜLeft ventricle ejection fraction%, Difference in Left ventricle ejection fraction% from baseline to 3 months after Nivolumab administration., 3 months|‚àÜLeft ventricle end systolic volume/Body surface area, Difference in Left ventricle end systolic volume/Body surface area from baseline to 3 months after Nivolumab administration., 3 months|‚àÜLeft ventricle end diastolic volume/Body surface area, Difference in Left ventricle end diastolic volume/Body surface area from baseline to 3 months after Nivolumab administration., 3 months|‚àÜTroponin T, Difference in concentration of Troponin T from baseline to 3 months after Nivolumab administration., 3 months|‚àÜproBNP, Difference in concentration of proBNP from baseline to 3 months after Nivolumab administration., 3 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         1\n",
      "Name: count, Length: 5920, dtype: int64\n",
      "\n",
      "Value counts for 'sponsor':\n",
      "sponsor\n",
      "Fudan University                               170\n",
      "M.D. Anderson Cancer Center                    109\n",
      "Sun Yat-sen University                         106\n",
      "National Cancer Institute (NCI)                 93\n",
      "Memorial Sloan Kettering Cancer Center          85\n",
      "                                              ... \n",
      "Jianjun Yang,MD                                  1\n",
      "Jianhui Tian                                     1\n",
      "Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.      1\n",
      "Jiangsu Simcere Pharmaceutical Co., Ltd.         1\n",
      "Ê±†Áïî                                               1\n",
      "Name: count, Length: 2218, dtype: int64\n",
      "\n",
      "Value counts for 'study_type':\n",
      "study_type\n",
      "INTERVENTIONAL    6676\n",
      "Name: count, dtype: int64\n",
      "\n",
      "Value counts for 'study_design':\n",
      "study_design\n",
      "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT                                                                           2168\n",
      "Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT                                                                       1456\n",
      "Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT                                                                    426\n",
      "Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT     421\n",
      "Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT                                                                  367\n",
      "                                                                                                                                                                   ... \n",
      "Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT                      1\n",
      "Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE                                                   1\n",
      "Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE                                                     1\n",
      "Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION                                                  1\n",
      "Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT                                                      1\n",
      "Name: count, Length: 183, dtype: int64\n",
      "\n",
      "Value counts for 'locations':\n",
      "locations\n",
      "Not specified                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        704\n",
      "M D Anderson Cancer Center, Houston, Texas, 77030, United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      63\n",
      "National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               60\n",
      "Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 200032, China                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            57\n",
      "Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, China                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             37\n",
      "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ... \n",
      "Henan Provincial Cancer Hospital, Zhengzhou, Henan, 450000, China                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1\n",
      "Henan Provincial People's Hospital, Zhengzhou, Henan, China|Hubei Cancer Hospital, Wuhan, Hubei, China|The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, China|the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China|Shandong Cancer Hospital & Institute, Jinan, Shandong, China|Sichuan Cancer Hospital, Chengdu, Sichuan, China|Sichuan Provincial People's Hospital, Chengdu, Sichuan, China|Ningbo No.2 Hospital, Ningbo, Zhejiang, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China      1\n",
      "Henan Tumor Hospital, Zhengzhou, Henan, 450000, China                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  1\n",
      "HenanCH, Zhengzhou, Henan, 450000, China                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               1\n",
      "Âåó‰∫¨È´òÂçöÂåªÈô¢, Âåó‰∫¨, Âåó‰∫¨Â∏ÇÊòåÂπ≥Âå∫, 102200, China                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1\n",
      "Name: count, Length: 4716, dtype: int64\n"
     ]
    }
   ],
   "source": [
    "for col in df.select_dtypes(include='category').columns:\n",
    "    print(f\"\\nValue counts for '{col}':\")\n",
    "    try:\n",
    "        print(df[col].value_counts())\n",
    "    except Exception as e:\n",
    "        print(f\"Could not display value counts for '{col}': {e}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "id": "52111bfc",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "study_title                        0\n",
      "study_status                       0\n",
      "brief_summary                      0\n",
      "conditions                         0\n",
      "interventions                      0\n",
      "primary_outcome_measures           0\n",
      "secondary_outcome_measures         0\n",
      "sponsor                            0\n",
      "enrollment                         0\n",
      "study_type                         0\n",
      "study_design                       0\n",
      "last_update_posted                 0\n",
      "locations                          0\n",
      "study_duration_days                0\n",
      "sex_all                            0\n",
      "sex_female                         0\n",
      "sex_male                           0\n",
      "has_child                          0\n",
      "has_adult                          0\n",
      "has_older_adult                    0\n",
      "phase1                             0\n",
      "phase2                             0\n",
      "phase3                             0\n",
      "funder_fed                         0\n",
      "funder_indiv                       0\n",
      "funder_industry                    0\n",
      "funder_network                     0\n",
      "funder_nih                         0\n",
      "funder_other                       0\n",
      "funder_other_gov                   0\n",
      "funder_unknown                     0\n",
      "missing_start_date                 0\n",
      "missing_primary_completion_date    0\n",
      "missing_completion_date            0\n",
      "dtype: int64\n"
     ]
    }
   ],
   "source": [
    "print(df.isnull().sum())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "cfad79ca",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(6676, 34)"
      ]
     },
     "execution_count": 49,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e2c67618",
   "metadata": {},
   "source": [
    "#### Saved cleaned data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "id": "84bc8b51",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.to_csv('../data/processed/merged_cleaned_trials.csv', index=True)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "nova",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
